Figure 2.

BR101801, a novel PI3K inhibitor, effectively inhibits proliferation of various DLBCL cell lines. A. In vitro selectivity of BR1010801 on different PI3K subtypes was studied in cell-free systems using Homogenous Time Resolved Fluorescence (HTRF) analysis. B. Growth inhibition (GI50) of DLBCL cells by BR101801. The in vitro anti-cancer effects of BR101801 were confirmed in various cell lines. C. Flow cytometry was performed to detect cell cycle distribution. After treatment with BR101801 (0-0.01 μM) for 16 h, the DLBCL cell lines were subjected to a propidium iodide (PI) staining assay.